Controlling plasma protein binding: Structural correlates of interactions of hydrophobic polyamine endotoxin sequestrants with human serum albumin

Molecular Pharmaceutics

Volumn 5, Issue 6, 2008, Pages 1131-1137

  Nguyen, Thuan B ^a   Kumar, E V K Suresh ^a   Sil, Diptesh ^a   Wood, Stewart J ^a   Miller, Kelly A ^a   Warshakoon, Hemamali J ^a   Datta, Apurba ^a   David, Sunil A ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

Albumin; Endotoxin sequestrants; Lipopolyamines; Plasma protein binding

Indexed keywords

CARBAMIC ACID; CARBONYL DERIVATIVE; ENDOTOXIN; FATTY ACID BINDING PROTEIN; HUMAN SERUM ALBUMIN; LIPOPOLYAMINE; LIPOPOLYSACCHARIDE; POLYAMINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CONCENTRATION (PARAMETERS); DISSOCIATION CONSTANT; ENTHALPY; FLUORESCENCE SPECTROSCOPY; HYDROPHOBICITY; ISOTHERMAL TITRATION CALORIMETRY; PHARMACODYNAMICS; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

BINDING SITES; BLOOD PROTEINS; ENDOTOXINS; HUMANS; HYDROPHOBICITY; LIPOSOMES; MOLECULAR STRUCTURE; POLYAMINES; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SERUM ALBUMIN;

EID: 64549140875     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp8001123     Document Type: Article

References (65)

1. Luderitz, O.; Galanos, C.; Rietschel, E. T. Endotoxins of Gram- negative bacteria. Pharmacol. Ther. 1982, 15, 383-402.
2. Rietschel, E. T.; Kirikae, T.; Schade, F. U.; Mamat, U.; Schmidt, G.; Loppnow, H.; Ulmer, A. J.; Zahringer, U.; Seydel, U.; Di Padova, F.; et al. Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB J. 1994, 8, 217-225.
3. Rietschel, E. T.; Brade, L.; Lindner, B.; Zähringer, U. Biochemistry of lipopolysaccharides. In Bacterial endotoxic lipopolysac- charides, vol. I. Molecular biochemistry and cellular biology; Morrison, D. C., Ryan, J. L., Eds.; CRC Press: Boca Raton, 1992; pp 1-41.
4. Holst, O.; Ulmer, A. J.; Brade, H.; Rietschel, E. T. On the chemistry and biology of bacterial endotoxic lipopolysaccharides. In Immunotherapy of infections; Masihi, N., Ed.; Marcel Dekker, Inc.: New York, Basel, Hong Kong, 1994; pp 281-308.
5. Rietschel, E. T.; Wollenweber, H. W.; Sidorczyk, Z.; Zähringer, U.; Luderitz, O. Analysis of the primary structure of lipid A. In Bacterial Lipopolysaccharides: Structure, Synthesis and Biological Activities; Anderson, L., Unger, F. M., Eds.; Am. Chem. Soc. Symp. Ser.; American Chemical Society: Washington, DC, 1983; pp 195-212.
6. Hoffman, W. D.; Natanson, C. Endotoxin in septic shock. Anesth. Analg. 1993, 77, 613-624.
7. Bone, R. C.; Sprung, C. L.; Sibbald, W. J. Definitions for sepsis and organ failure. Crit. Care Med. 1992, 20, 724-726.
8. Bone, R. C.; Balk, R. A.; Cerra, F. B.; Dellinger, R. P.; Fein, A. M.; Knaus, W. A.; Schein, R. M.; Sibbald, W. J. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101, 1644-1655.
9. Bone, R. C. The sepsis syndrome. Definition and general approach to management. Clin. Chest Med. 1996, 17, 175-181.
10. Ulevitch, R. J. Molecular mechanisms of innate immunity. Immunol. Res. 2000, 21, 49-54.
11. Ulevitch, R. J.; Tobias, P. Recognition of gram-negative bacteria and endotoxin by the innate immune system. Curr. Opin. Immunol. 1999, 11, 19-23.
12. Dinarello, C. A. Cytokines as mediators in the pathogenesis of septic shock. Curr. Toy. Microbiol. Immunol. 1996, 216, 133-165.
13. Dinarello, C. A. Interleukin-1 and its biologically related cytokines. Adv. Immunol. 1989, 44, 153-205.
14. Dinarello, C. A. The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome. J. Infect. Dis. 1991, 163, 1177-1184.
15. Michie, H. R.; Manogue, K. R.; Spriggs, D. R.; Revhaug, A.; O'Dwyer, S.; Dinarello, C. A.; Cerami, A.; Wolff, S. M.; Wilmore, D. W. Detection of circulating tumor necrosis factor after endotoxin administration. N. Engl. J. Med 1988, 318, 1481-1486.
16. Burns, M. R.; Wood, S. J.; Miller, K. A.; Nguyen, T.; Cromer, J. R.; David, S. A. Lysine-spermine conjugates: hydrophobic polyamine amides as potent lipopolysaccharide sequestrants. Bioorg. Med. Chem. 2005, 13, 2523-2536.
17. Burns, M. R.; Jenkins, S. A.; Kimbrell, M. R.; Balakrishna, R.; Nguyen, T. B.; Abbo, B. G.; David, S. A. Polycationic sulfonamides for the sequestration of endotoxin. J. Med. Chem. 2007, 50, 877-888.
18. Burns, M. R.; Jenkins, S. A.; Vermeulen, N. M.; Balakrishna, R.; Nguyen, T. B.; Kimbrell, M. R.; David, S. A. Structural correlation between lipophilicity and lipopolysaccharide-sequester- ing activity in spermine-sulfonamide analogs. Bioorg. Med. Chem. Lett. 2006, 16, 6209-6212.
19. Burns, M. R.; Jenkins, S. A.; Wood, S. J.; Miller, K.; David, S. A. Structure-activity relationships in lipopolysaccharide neutralizers: design, synthesis, and biological evaluation of a 540-membered amphipathic bisamide library. J. Comb. Chem. 2006, 8, 32-43.
20. David, S. A.; Awasthi, S. K.; Balaram, P. The role of polar and facial amphipathic character in determining lipopolysaccharide- binding properties in synthetic cationic peptides. J. Endotoxin Res. 2000, 6, 249-256.
21. Guo, J. X.; Wood, S. J.; David, S. A.; Lushington, G. H. Molecular modeling analysis of the interaction of novel bis-cationic ligands with the lipid A moiety of lipopolysaccharide. Bioorg. Med. Chem. Lett. 2006, 16, 714-717.
22. Khownium, K.; Wood, S. J.; Miller, K. A.; Balakrishna, R.; Nguyen, T. B.; Kimbrell, M. R.; Georg, G. I.; David, S. A. Novel endotoxin-sequestering compounds with terephthalaldehyde-bis- guanylhydrazone scaffolds. Bioorg. Med. Chem. Lett. 2006, 16, 1305-1308.
23. Miller, K. A.; Suresh Kumar, E. V. K.; Wood, S. J.; Cromer, J. R.; Datta, A.; David, S. A. Lipopolysaccharide Sequestrants: Structural Correlates of Activity and Toxicity in Novel Acylho-mospermines. J. Med. Chem. 2005, 48, 2589-2599.
24. Nguyen, T. B.; Adisechan, A.; Suresh Kumar, E. V. K.; Bal- akrishna, R.; Kimbrell, M. R.; Miller, K. A.; Datta, A.; David, S. A. Protection from Endotoxic Shock by EVK-203, a Novel Alkylpolyamine Sequestrant of Lipopolysaccharide. Bioorg. Med. Chem. 2007, 15, 5694-5709.
25. Sil, D.; Shrestha, A.; Kimbrell, M. R.; Nguyen, T. B.; Adisechan, A. K.; Balakrishna, R.; Abbo, B. G.; Malladi, S.; Miller, K. A.; Short, S.; Cromer, J. R.; Arora, S.; Datta, A.; David, S. A. Bound to Shock: Protection from Lethal Endotoxemic Shock by a Novel, Nontoxic, Alkylpolyamine Lipopolysaccharide Sequestrant. An- timicrob. Agents Chemother. 2007, 51, 2811-2819.
26. Wood, S. J.; Miller, K. A.; Lushington, G. H.; Burns, M. R.; David, S. A. Anti-endotoxin agents. 3. Rapid identification of high- affinity lipopolysaccharide-binding compounds in a substituted polyamine library. Comb. Chem. High Throughput Screening 2006, 9, 27-36.
27. Beutler, B.; Poltorak, A. The sole gateway to endotoxin response: how LPS was identified as TLR4, and its role in innate immunity. Drug Metab. Dispos. 2001, 29, 474-478.
28. Ingalls, R. R.; Heine, H.; Lien, E.; Yoshimura, A.; Golenbock, D. Lipopolysaccharide recognition, CD14, and lipopolysaccharide receptors. Infect. Dis. Clin. North Am. 1999, 13, 341-53, vii.
29. Lien, E.; Means, T. K.; Heine, H.; Yoshimura, A.; Kusumoto, S.; Fukase, K.; Fenton, M. J.; Oikawa, M.; Qureshi, N.; Monks, B.; Finberg, R. W.; Ingalls, R. R.; Golenbock, D. T. Toll-like receptor 4 imparts ligand-specific recognition of bacterial li- popolysaccharide. J. Clin. Invest. 2000, 105, 497-504.
30. Poltorak, A.; He, X.; Smirnova, I.; Liu, M. Y.; Huffel, C. V.; Du, X.; Birdwell, D.; Alejos, E.; Silva, M.; Galanos, C.; Freudenberg, M.; Ricciardi, C. P.; Layton, B.; Beutler, B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998, 282, 2085-2088.
31. Ulevitch, R. J.; Tobias, P. S. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu. Rev. Immunol. 1995, 13, 437-457.
32. Ulevitch, R. J. Recognition of bacterial endotoxins by receptor- dependent mechanisms. Adv. Immunol. 1993, 53, 267-289.
33. Marshall, J. C. Such stuff as dreams are made on: Mediator- directed therapy in sepsis. Nat. Rev. Drug Discovery 2003, 2, 391-405.
34. Zeni, F.; Freeman, B.; Natanson, C. Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment. Crit. Care Med. 1997, 25, 1097-1100.
35. Fasano, M.; Curry, S.; Terreno, E.; Galliano, M.; Fanali, G.; Narciso, P.; Notari, S.; Ascenzi, P. The extraordinary ligand binding properties of human serum albumin. IUBMB Life 2005, 57, 787-796.
36. Bertucci, C.; Domenici, E. Reversible and covalent binding of drugs to human serum albumin: methodological approaches and physiological relevance. Curr. Med. Chem. 2002, 9, 1463-1481.
37. Kratz, F. Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles J. Controlled Release, in press.
38. Scheife, R. T. Protein binding: what does it mean? DICP 1989, 25, S27-S31.
39. Tillement, J. P.; Urien, S.; Chaumet-Riffaud, P.; Riant, P.; Bree, F.; Morin, D.; Albengres, E.; Barre, J. Blood binding and tissue uptake of drugs. Recent advances and perspectives. Fundam. Clin. Pharmacol. 1988, 2, 223-238.
40. Koch-Weser, J.; Sellers, E. M. Binding of drugs to serum albumin (first of two parts). N. Engl. J. Med 1976, 294, 311-316.
41. Jusko, W. J.; Gretch, M. Plasma and tissue protein binding of drugs in pharmacokinetics. Drug Metab Rev. 1976, 5, 43-140.
42. du Souich, P.; Verges, J.; Erill, S. Plasma protein binding and pharmacological response. Clin. Pharmacokinet. 1993, 24, 435-440.
43. David, S. A.; Balaram, P.; Mathan, V. I. Characterization of the interaction of lipid A and lipopolysaccharide with human serum albumin: implications for an endotoxin-carrier function for albumin. J. Endotoxin. Res. 1995, 2, 99-106.
44. Wood, S. J.; Miller, K. A.; David, S. A. Anti-endotoxin agents. 2. Pilot high-throughput screening for novel lipopolysaccharide- recognizing motifs in small molecules. Comb. Chem. High Throughput Screening 2004, 7, 733-743.
45. He, X. M.; Carter, D. C. Atomic structure and chemistry of human serum albumin. Nature 1992, 358, 209-215.
46. Sudlow, G.; Birkett, D. J.; Wade, D. N. Further characterization of specific drug binding sites on human serum albumin. Mol. Pharmacol. 1976, 12, 1052-1061.
47. Sudlow, G.; Birkett, D. J.; Wade, D. N. The characterization of two specific drug binding sites on human serum albumin. Mol. Pharmacol. 1975, 11, 824-832.
48. Pliska, V. Displacement reactions employing heterologous tracer ligands in peptide receptor studies: a review. J. Recept. Res. 1983, 3, 227-238.
49. Birkett, D. J.; Myers, S. P.; Sudlow, G. Effects of Fatty Acids on Two Specific Drug Binding Sites on Human Serum Albumin. Mol. Pharmacol. 1977, 13, 987-992.
50. Horovitz, A.; Levitzki, A. An accurate method for determination of receptor-ligand and enzyme-inhibitor dissociation constants from displacement curves. Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 6654-6658.
51. Curry, S.; Mandelkow, H.; Brick, P.; Franks, N. Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Nat. Struct. Biol. 1998, 5, 827-835.
52. Fitz, J. G.; Bass, N. M.; Weisiger, R. A. Hepatic transport of a fluorescent stearate derivative: electrochemical driving forces in intact rat liver. Am. J. Physiol. 1991, 261, G83-G91.
53. Luxon, B. A.; Milliano, M. T. Cytoplasmic codiffusion of fatty acids is not specific for fatty acid binding protein. Am. J. Physiol. 1997, 275, C859-C867.
54. Berde, C. B.; Kerner, J. A.; Johnson, J. D. Use of the conjugated polyene fatty acid, parinaric acid, in assaying fatty acids in serum or plasma. Clin. Chem. 1980, 26, 1173-1177.
55. Berde, C. B.; Hudson, B. S.; Simoni, R. D.; Sklar, L. A. Human serum albumin. Spectroscopic studies of binding and proximity relationships for fatty acids and bilirubin. J. Biol. Chem. 1979, 254, 391-400.
56. Aki, H.; Yamamoto, M. Thermodynamic characterization ofdrug binding to human serum albumin by isothermal titration micro- calorimetry. J. Pharm. Sci. 1994, 85, 1712-1716.
57. Aki, H.; Yamamoto, M. Thermodynamic aspects of fatty acids binding to human serum albumin: a microcalorimetric investigation. Chem. Pharm. Bull. (Tokyo) 1992, 40, 1553-1558.
58. Aki, H.; Yamamoto, M. Biothermodynamic characterization of monocarboxylic and dicarboxylic aliphatic acids binding to human serum albumin: a flow microcalorimetric study. Biophys. Chem. 1993, 46, 91-99.
59. Fang, Y.; Tong, G. C.; Means, G. E. Structural changes accompanying human serum albumin's binding of fatty acids are concerted. Biochim. Biophys. Acta 2006, 1764, 285-291.
60. Rosseneu, M.; Soetewey, F.; Blaton, V.; Lievens, J.; Peeters, H. Application of microcalorimetry to the study of lipid-protein interaction. Chem. Phys. Lipids 1976, 17, 38-56.
61. Aki, H.; Yamamoto, M. Thermodynamic characterization ofdrug binding to human serum albumin by isothermal titration microcalorimetry. J. Pharm. Sci. 1994, 85, 1712-1716.
62. David, S. A. Towards a rational development of anti-endotoxin agents: novel approaches to sequestration of bacterial endotoxins with small molecules. J. Mol. Recognit. 2001, 14, 370-387.
63. Kurtzhals, P. Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir Int. J. Obes. Relat. Metab. Disord. 2004, 28 (Suppl. 2), S23-S28.
64. Home, P.; Kurtzhals, P. Insulin detemir: from concept to clinical experience. Expert. Opin. Pharmacother. 2006, 7, 325-343.
65. Shrestha, A.; Li, R.; Sil, D.; Pardeshi, N. N.; Schwarting, N.; Schorno, K. S.; Rajewski, R. A.; Datta, A.; David, S. A. Pharmacokinetics of DS-96, an alkylpolyamine lipopolysaccharide sequestrant, in rodents J. Pharm. Sci., in press.